Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Albireo Pharma Inc (NQ: ALBO )

34.85 USD +0.98 (+2.89%)
Official Closing Price Updated: 5:29 PM EST, Mar 5, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Press releases about Albireo Pharma Inc

< Previous 1 2 3 4 5 Next >
Albireo Spotlights Global Patient Communities on Rare Disease Day
From GlobeNewswire News Releases
Albireo Reports Q4 and Year-End 2020 Financial Results and Business Update
From GlobeNewswire News Releases
Albireo to Participate in Cowen and H.C. Wainwright Global Investor Conferences
From GlobeNewswire News Releases
Albireo to Report Q4 and Year-End 2020 Financial Results on February 25
Conference call and webcast to be held at 10:00 a.m. ET 
From GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Albireo Presents Odevixibat Commercialization Road to $1 Billion
From GlobeNewswire News Releases
Albireo Announces U.S. FDA Acceptance of New Drug Application for Odevixibat
From GlobeNewswire News Releases
Albireo Recognizes International Alagille Syndrome Awareness Day 2021
Albireo supports the Alagille syndrome community to advocate for more education and new treatment advances for rare cholestatic liver diseases 
From GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Albireo to Host Virtual Investor Commercial Day 2021
From GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Albireo to Participate in H.C. Wainwright BioConnect and LifeSci Advisors Investor Conferences
From GlobeNewswire News Releases
Albireo Initiates Global Phase 3 Clinical Trial of Odevixibat in Alagille Syndrome
From GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Albireo Submits for U.S. FDA and EMA Product Approval of Once-Daily Odevixibat for PFIC
From GlobeNewswire News Releases
New Phase 3 Data at AASLD Show Durable Response to Odevixibat in a Rare Pediatric Liver Disease
From GlobeNewswire News Releases
Albireo to Participate in Jefferies and Piper Sandler Virtual Investor Conferences
From GlobeNewswire News Releases
Albireo Reports Q3 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Albireo’s Odevixibat PFIC Phase 3 Results Accepted for AASLD Late-Breakers
From GlobeNewswire News Releases
Albireo Announces Presentations at NASPGHAN 2020 Annual Meeting
From GlobeNewswire News Releases
Albireo Recognizes PFIC Awareness Day 2020
Albireo stands together with the PFIC community to highlight critical need for education and advances in research for rare cholestatic liver diseases 
From GlobeNewswire News Releases
Albireo Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)
From GlobeNewswire News Releases
Albireo Prices Public Offering of 4,000,000 Shares of Common Stock
From GlobeNewswire News Releases
Albireo Announces Proposed Public Offering of 3,000,000 Shares of Common Stock
From GlobeNewswire News Releases
Albireo Phase 3 Trial Meets Both Primary Endpoints for Odevixibat in PFIC
From GlobeNewswire News Releases
Albireo to Announce Topline Results from PEDFIC 1 Phase 3 Trial of Odevixibat on September 8, 2020
— Conference call and webcast to be held at 8:30 a.m. EDT — 
From GlobeNewswire News Releases
Albireo Reports Topline Results from Phase 2 Trial of Elobixibat in NAFLD/NASH
From GlobeNewswire News Releases
Albireo Reports Q2 2020 Financial Results and Provides Business Update
From GlobeNewswire News Releases
Albireo to Present at the William Blair Biotech Focus Conference 2020
From GlobeNewswire News Releases
Albireo to Report Q2 2020 Financial Results on August 6
From GlobeNewswire News Releases
< Previous 1 2 3 4 5 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.